<unk>  (Cal/BD) is a topical medication for the treatment of trunk, limb, and scalp plaque psoriasis. This medication is available in ointment, gel, aerosol, or foam, formulations. The ointment formulation was FDA approved in 2004, and is indicated for the once daily topical treatment of plaque-type psoriasis vulgaris amenable to topical therapy. The foam formulation was approved by the FDA in 2015, and is indicated for the topical treatment of plaque psoriasis in patients twelve years of age and older. In all pivotal trials of<unk>  ointment, topical suspension, or foam, treatment success or achievement of 'clear' or 'almost clear' disease was defined by Investigator's Global Assessment, an alternative to the Psoriasis Area and Severity Index (PASI) score. ;Ointment In an international, double-blind, parallel group study of 1603 participants with psoriasis (affecting at least 10% of one or more body regions), more patients on once-daily<unk>  ointment had controlled disease, defined as having absence or very mild disease at 4 weeks (56.3%) compared with Cal 50 μg/g (22.3%). In addition, a retrospective analysis of data from six phase 3, double-blind studies found that more patients treated with<unk>  ointment achieved PASI 75 than patients treated with individual components, regardless of baseline disease severity. ;Foam The foam formulation has been studied in two pivotal, randomized, double-blind trials in patients with mild to severe plaque psoriasis. In the first study (randomized, phase 2) of 302 patients with body and scalp psoriasis, more patients treated with<unk>  (Cal/BD) foam achieved 'clear' or ' almost clear' disease (45%) according to the IGA by 4 weeks compared with Cal 50 mcg/g or BD 0.5 mg/g (15% and 31%, respectively). In a second study (randomized, phase 3) of patients with psoriasis on the body (N=426), a significantly greater proportion of patients treated with once-daily Cal/BD foam achieved 'clear' or 'almost clear' disease (53.3%) vs. those receiving the vehicle control (4.8%). Mean modified PASI score was also significantly lower for patients treated with Cal/BD foam compared with vehicle (2.0 vs 5.5, respectively, at week 4), and itch relief was significantly greater in patients using the Cal/BD foam beginning at day 3. A recent study compared the Cal/BD foam formulation with the ointment formulation in patients with mild to severe psoriasis. At 4 weeks, significantly more patients achieved treatment success, defined as 'clear' or 'almost clear' disease according to the IGA with Cal/BD foam (54.6%) versus the ointment (43.0%). However, pronounced itch relief occurred quickly and was maintained throughout the 4-week study duration with both formulations.
Calcipotriol/betamethasone dipropionate
Triamcinolone benetonide
Clotrimazole/betamethasone dipropionate
Tretinoin/benzoyl peroxide
Triamcinolone acetonide
Fluocinolone acetonide
Hydrocortisone/miconazole
Olopatadine/mometasone